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Seroepidemiology of Astrovirus MLB1
Lori R. Holtz,a Irma K. Bauer,a Hongbing Jiang,a Robert Belshe,b Pamela Freiden,c Stacey L. Schultz-Cherry,c David Wanga
Washington University School of Medicine, St. Louis, Missouri, USAa; Saint Louis University, St. Louis, Missouri, USAb; St. Jude Children’s Research Hospital, Memphis,
Tennessee, USAc
To determine the seroprevalence of astrovirus MLB1 (MLB1), an indirect enzyme-linked immunosorbent assay (ELISA) was es-
tablished. MLB1 seropositivity was high in children<6 months old, decreased to a nadir at 12 to 23 months old, and increased to
100% by adulthood. MLB1 infection is common, and primary exposure occurs in childhood.
Astroviruses were first discovered in humans in 1975. These“classic astroviruses” consist of eight closely related serotypes
that are responsible for about 10% of sporadic nonbacterial diar-
rhea in children. The extent of human infection by these viruses
varies, depending on serotype. For example, 90% of the general
population has antibodies to serotype 1, while only 10% has anti-
bodies to serotype 7 (1).
Recently a new clade of astroviruses has been identified.
This clade currently consists of astroviruses MLB1, MLB2, and
MLB3. All three viruses were initially discovered in stool sam-
ples from children with diarrhea (2–4) and have since been
detected in additional diarrhea cases as well as control stools (3,
5, 6). MLB1, MLB2, and MLB3 have not yet been associated
with any human disease, although we have detected MLB2 in
the plasma of a febrile child (7). A recent case control study of
MLB1 in a cohort of Indian children found no association of
MLB1 with diarrhea (5). Currently it is unclear if the presence
of these novel astroviruses in human stool samples represents
true human infection. Here we describe the first evidence of
human antibody response to MLB1 and demonstrate that in-
fection by MLB1 is common.
An enzyme-linked immunosorbent assay (ELISA) targeting
MLB1 open reading frame 2 (ORF2)was established and validated
using rabbit antibody raised against anMLB1 peptide as a positive
control and preimmune serum as a negative control. Polyclonal
MLB1 capsid peptide antibody (DW60) was generated by the im-
munization of rabbits with TNNQRARSTRPNFTPAPKF (posi-
tions 22 to 40) and ARRAMFDALVKTGVSVEEASR (positions
697 to 717) (21st Century Biochemicals). MLB2 capsid peptide
(ASNQRTRSAGPGPKC) (positions 22 to 35) andCPLPHRTIEW
DESSD (positions 646 to 659) (Genscript) were synthesized and
injected into rabbits to produce antibodies DW57 and DW58,
respectively. Open reading frames 2 (capsid protein) of MLB1,
MLB2, and MLB3 were cloned as follows. MLB1 (nucleotides
3843 to 6113 from GenBank accession no. NC_011400.1) flanked
with NotI and PstI restriction sites, MLB2 (nucleotides 3843 to
6080 from GenBank accession no. NC_016155.1) flanked with
NotI and XhoI restriction sites, and MLB3 (nucleotides 3843 to
6086 from GenBank accession no. NC_019028.1) flanked with
NotI and XhoI were amplified from stool RNA by reverse
transcription-PCR with the following primers: SF0118F (5=-
ATAGCGGCCGCATGGCTAATGCCAGTAAAGGTGT-3=) and
SF0111R (5=-ATAGACGTCTTATTTACAATTGTATGCTTCCT
CGT-3=) forMLB1, LG0166 (5=-ATAGCGGCCGCATGGCTAAT
GCCAATAAGGGTGT-3=) and LG0168 (5=-ATACTCGAGTTAT
TTGTCTAAAAGACATGCTTCGC-3=) for MLB2, and LG0205
(5=-ATAGCGGCCGCATGGCTAATGCCAATAAGGGTGTG-
3=) and LG0206 (5=-ATACTCGAGTTATTTGTCTAAAAGACA
TGCCTCA-3=) for MLB3. Recombinant baculoviruses were
generated by the Bac-to-Bac system (Invitrogen) per the man-
ufacturer’s protocol at the St. Jude’s Protein Production Core
Facility. Human astrovirus serotype 1 capsid protein was pro-
duced as previously described (8) with the following modifica-
tion: an N-terminal His tag was added to the previous con-
struct. Baculovirus-expressed His-tagged RANK protein was
kindly provided by Daved Fremont (9).
MLB1, MLB2, and MLB3 capsid proteins were expressed in a
baculovirus system as N-terminal 6His-tagged proteins and af-
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FIG 1 (A) Coomassie blue staining of a sodium dodecyl sulfate-polyacryl-
amide gel showing baculovirus-expressed His-taggedMLB1 (expected size, 88
kDa),MLB2 (expected size, 87 kDa), andMLB3 (expected size, 88 kDa) capsid
proteins. (B) Western blot using polyclonal MLB1 peptide antibody (DW60)
(1:500) against recombinant His-MLB1 capsid (5 ng) and polyclonal MLB2
peptide antibody (DW58) (1:2,500) against recombinant His-MLB2 capsid
(100 ng). Mock, protein lysate from uninfected Sf9 cells.
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finity purified using HiTrap chelating high-performance (HP)
columns (GE Healthcare). SDS-polyacrylamide gel electrophore-
sis and Coomassie staining were used to assess the purity of the
protein (Fig. 1A). Also, mass spectrometry was used to confirm
the mass of the major product. Additionally, a Western blot assay
using the polyclonal rabbit antibodies against MLB1 and MLB2
capsid gave signals of approximately the expected size (88 kDA for
MLB1 and 87 kDA for MLB2) (Fig. 1B).
We analyzed 395 deidentified sera from subjects 2 months to
95 years of age, which were obtained from healthy volunteers in
North America for previous studies conducted at the Saint Louis
University Center for Vaccine Development collected between
1984 and 2009 (examples of studies include references 10 and 11).
The ages of the subjects and numbers of sera were as follows: 0 to
6months,n 22; 7 to 11months,n 23; 12 to 23months,n 35;
2 years, n 13; 3 years, n 20; 4 to 6 years, n 47; 7 to 17 years,
n  75; 18 to 32 years, n  38; 33 to 64 years, n  42; and 65
years, n 80. The institutional review boards at Saint Louis Uni-
versity and Washington University School of Medicine approved
this study.
ELISAs were optimized and performed as described previously
(12) with the following changes: horseradish peroxidase-conju-
gated protein A/G (Thermo-Scientific) (which binds IgG, IgM,
and IgA) diluted 1:10,000 was used, theHis-MLB1 capsid concen-
tration was 25 ng/well, and the His-MLB2 capsid concentration
was 75 ng/well. For the preincubation assays, serum samples were
diluted in blocking buffer and preincubated overnight at 4°C with
10 the coating amount (250 ng for MLB1 plates or 750 ng for
MLB2 plates) of recombinant His-MLB1 capsid, His-MLB2 cap-
sid, His-MLB3 capsid, His-human astrovirus 1 capsid, or His-
RANK (an irrelevant protein). To establish the cutoff value, we
calculated the average of the 30 lowest serum samples and set the
cutoff 3 standard deviations (SD) above this mean (for MLB1,
mean of 30 lowest  0.283 OD units, SD  0.06988 OD units,
cutoff 0.492 OD units; for MLB2, mean of 30 lowest 0.2011
OD units, SD 0.03677 OD units, cutoff 0.311 OD units). To
assess plate-to-plate variation, preimmune rabbit serum and
MLB1 peptide antibody (DW60) were analyzed on every ELISA
plate. The coefficient of variance for the preimmune rabbit serum
was 14.80% (MLB1), and that for the positive control was 26.17%
(MLB1).
In a cohort of healthy vaccine trial participants, the overall
FIG 2 ELISA results for MLB1. A total of 395 serum samples were assayed for antibodies against MLB1 capsid protein.
FIG 3 Effects of preincubation with MLB1, MLB2, MLB3, HAstV1, and RANK on MLB1 ELISA. Human serum samples were preincubated with each protein
individually prior to the ELISA. The positive controls were polyclonal MLB1 peptide antibody (DW60) from each plate.
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seropositivity of MLB1 was 86.6% (342/395). Anti-MLB1 capsid
antibodies appear to be maternally transferred based on the rela-
tively high seroprevalence in the 0- to 6-month age group (68.1%)
coupled with a lower positivity rate (31.4%) in the 12- to 23-
month age group. The seropositivity rate then rapidly increased
and reached 100% in the 7- to 17-year age group (Fig. 2) and
remained high thereafter. Thus,MLB1 seroepidemiology parallels
that of human astrovirus 1 but is in contrast to the low seropreva-
lence rates of human astrovirus 7 (1).
To assess the specificity of the MLB1 assay, preincubation as-
says were performed on 10 serum samples arbitrarily chosen
among sampleswith high-intensity signal (optical density [OD] of
2.400). Preincubation with His-MLB1 capsid reduced the
ELISA signal on average by 70%; in contrast, the signal remained
constant when preincubated with His-HAstV-1, His-MLB2, His-
MLB3, and His-RANK (Fig. 3). Sample 10 did not compete with
any antigen, including His-MLB1, at the standard 1:100 serum
dilution; however, competition was observed with His-MLB1 but
not the other proteins at a more dilute serum concentration (1:
800), suggesting that this sample had high-titer MLB1 antibodies
(data not shown).
We also attempted to define the seroprevalence of MLB2 by
using a parallel ELISA approach with MLB2 capsid as the target
antigen. A total of 89.4% of the cohort was positive in this
assay. However, preincubation experiments done on 20 sam-
ples (10 arbitrarily chosen among samples with high-intensity
signal [OD of 2.400] and 10 randomly selected from the co-
hort) demonstrated significant levels of cross-reaction with
MLB1 (50% of samples) and MLB3 (20% of samples), thus
precluding definitive interpretation of these results (Fig. 4).
This type of one-way cross-reactivity has been described for
other viruses (13). We did not evaluate MLB3 seropositivity in
an ELISA sinceMLB3 andMLB2 share 89% amino acid identity
in the capsid region. In the future, the development of more
specific serologic assays, such as a neutralization assay or the
use of monoclonal antibodies will be needed to explicitly define
the levels of MLB2 and MLB3 seropositivity and to determine
whether these are distinct serotypes.
The potential role that the MLB clade astroviruses may play in
human disease is currently unknown. These viruses might cause
diarrhea like the canonical human astrovirus serotypes 1 to 8,
although we cannot discount the possibility that they may have
other pathogenic potential in the gastrointestinal (GI) tract or
elsewhere. We recently described a febrile patient viremic with
MLB2 (7), raising the possibility that MLB2 may be involved in
fever; another implication of that study is that MLB2, and thus
possibly other astroviruses as well, can clearly access cellular com-
partments outside the GI tract via the circulatory system. Indeed,
a distinct novel astrovirus has been reported in brain tissue of an
immunocompromised patient with encephalitis (14), and sero-
logic analysis demonstrates that infection with this astrovirus is
relatively common (15). Thus, the high rates of seropositivity
againstMLB1 observed in this study underscore the need to define
FIG4 Effects of preincubationwithMLB1,MLB2,MLB3,HAstV1, andRANKonMLB2 ELISA. Samples were preincubatedwith each protein individually prior
to the ELISA.
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potential disease states that may be linked to this common hu-
man-infecting virus.
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